- BNGO is embarking on an ambitious plan to change the lab and diagnostics standards, putting the proceeds of the new equity offering into good use.
- Although the company achieved high growth in Q1, it stems from a low base, making it hard to justify current price levels, even if the revenue momentum continues.
- I believe that BNGO has an aggressive investor base, with a high tolerance for risk, opening an opportunity for capital appreciation if BNGO surprises investors with higher than expected growth.
For further details see:
Nouveau Riche Bionano Realizing What Money Can't Buy